Grundläggande statistik
| LEI | 529900SSN4DODDQSN594 |
| CIK | 1177648 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Enanta Pharmaceuticals, Inc.
SEC Filings (Chronological Order)
Denna sida innehåller en komplett, kronologisk lista över SEC-arkiveringar, exklusive ägande-arkiveringar som vi tillhandahåller på andra ställen.
| May 13, 2026 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 13, 2026 S-8 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 13, 2026 REGISTRATION NO. |
|
| May 13, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q e UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registran |
|
| May 13, 2026 |
Table 1: Newly Registered Securities Calculation of Filing Fee Tables S-8 ENANTA PHARMACEUTICALS INC Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee 1 Equity Common stock, $0. |
|
| May 11, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2026 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 11, 2026 |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2026 • Dosing Initiated in a Phase 1 Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor in Development for the Treatment of Chronic Urticaria; On Track to Report Topline Data in 4Q 2026 • Conducting Enabling Activities for a Pivotal Study of Zelicapavir in High-Risk Adults with Respiratory |
|
| March 26, 2026 |
FORM 8-K Item 8.01 Other Events. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 20, 2026 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 12, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 11, 2026 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 12, 2026 |
ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended through March 11, 2026) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended through March 11, 2026) 1. Purpose The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected |
|
| February 17, 2026 |
February 17, 2026 Jay R. Luly, Ph.D. Chief Executive Officer Enanta Pharmaceuticals Inc. 4 Kingsbury Avenue Watertown, Massachusetts 02472 Re: Enanta Pharmaceuticals Inc. Registration Statement on Form S-3 Filed February 11, 2026 File No. 333-293390 Dear Jay R. Luly, Ph.D.: This is to advise you that we have not reviewed and will not review your registration statement. Please refer to Rules 460 an |
|
| February 17, 2026 |
CORRESP February 17, 2026 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| February 9, 2026 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025 • Conducting Phase 3 Enabling Activities, Including Discussions with U.S. Food & Drug Administration (FDA), for Zelicapavir, an N-Protein Inhibitor in Development to Treat Respiratory Syncytial Virus (RSV) • Introduced New Immunology Program Focused on MRGPRX2 Inhibition; On Track to |
|
| February 9, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 09, 2026 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| January 26, 2026 |
Annual Report 2025January 15, 2026 All of us at Enanta are committed to leveraging our expertise in small molecule drug discovery to develop novel, best-in-class medicines to transform the lives of patients with viral infections and immunological diseases. |
|
| January 26, 2026 |
DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidenti |
|
| January 26, 2026 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| November 19, 2025 |
Enanta Pharmaceuticals, Inc. Subsidiaries of the Company Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| November 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 17, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 17, 2025 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year -Ended September 30, 2025 • Announces EPS-3903, an Oral, Once-Daily STAT6 Inhibitor Development Candidate with Rapid, Continuous and Complete (>90%) In Vivo pSTAT6 Suppression and Efficacy Comparable to Dupilumab in Asthma and Atopic Dermatitis Disease Models • Announces EDP-978, an Oral, Once-Dail |
|
| October 1, 2025 |
Common Stock Preferred Stock Debt Securities 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275723 Prospectus supplement (To Prospectus dated February 8, 2024) 6,500,000 Shares Common stock We are offering 6,500,000 shares of our common stock, $0.01 par value per share, pursuant to this prospectus supplement and the accompanying prospectus. Our common stock is listed on the Nasdaq Global Select Market under the |
|
| October 1, 2025 |
Enanta Pharmaceuticals, Inc. 6,500,000 Shares of Common Stock Underwriting Agreement EX-1.1 Exhibit 1.1 Enanta Pharmaceuticals, Inc. 6,500,000 Shares of Common Stock Underwriting Agreement September 30, 2025 J.P. Morgan Securities LLC Jefferies LLC Evercore Group L.L.C. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o Jefferies LLC 520 Madison Avenue New York, NY 10022 c/o Evercore G |
|
| October 1, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 30, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 30, 2025 |
Common Stock Preferred Stock Debt Securities 424B5 Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-275723 The information in this preliminary prospectus supplement is not complete and may be changed. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell these securities, and we are not soliciting offers to buy these securities in any jurisdiction where the offer or sale is not |
|
| September 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 29, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 29, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Co |
|
| September 29, 2025 |
EX-99.1 Exhibit 99.1 Enanta Pharmaceuticals Reports Positive Topline Results from its Phase 2b Study of Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) in High-Risk Adults • 6.7-Day Improvement in Time to Complete Resolution of All RSV Symptoms for Patients with Chronic Obstructive Pulmonary Disease (COPD), Congestive Heart Failure (CHF), or Age ≥ 75 • Statistically Significant |
|
| September 29, 2025 |
EX-99.1 Phase 2b Study of Zelicapavir in High-Risk Adults: RSVHR Topline Results September 29, 2025 Exhibit 99.1 This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statemen |
|
| August 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 20, 2025 |
Exhibit 99.1 Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union WATERTOWN, Mass.—August 20, 2025- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unifi |
|
| August 20, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 13, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 11, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 11, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 11, 2025 |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2025 • On Track to Report Topline Data for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in September • On Track to Select a STAT6 Development Candidate in 2H 2025 • Conducting IND Enabling Studies of EPS-1421, an Oral KIT Inhibitor |
|
| May 14, 2025 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 14, 2025 S-8 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 14, 2025 REGISTRATION NO. |
|
| May 14, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 14, 2025 |
EX-FILING FEES EXHIBIT 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Enanta Pharmaceuticals, Inc. |
|
| May 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 12, 2025 |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2025 • Met Target Enrollment for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV); On Track to Report Topline Data in Late 3Q 2025 • STAT6 Program Progressing with Plans to Select a Development Candidate in 2H 2025 • IND Enabling Studi |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 13, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 17, 2025 |
2019 Equity Incentive Plan (as amended March 2025) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended through March 13, 2025) 1. Purpose The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected |
|
| February 12, 2025 |
2024 Inducement Stock Incentive Plan (as amended December 2024) Exhibit 10.2 ENANTA PHARMACEUTICALS, INC. 2024 Inducement Stock Incentive Plan (As amended through December 20, 2024) 1. Purpose The purpose of this 2024 Inducement Stock Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract persons who are expecte |
|
| February 12, 2025 |
2019 Equity Incentive Plan (as amended December 2024) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended through December 20, 2024) 1. Purpose The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expect |
|
| February 12, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 11, 2025 |
JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) EXHIBIT 1 JOINT ACQUISITION STATEMENT PURSUANT TO SECTION 240.13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the necessity of filing additional joint acquisition statements. The un |
|
| February 10, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 10, 2025 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 10, 2025 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2024 • On Track to Report Topline Results for RSVHR, a Phase 2 Study of Zelicapavir in High-Risk Adults Infected with Respiratory Syncytial Virus (RSV), in 3Q 2025 • Advancing Immunology Portfolio with Ongoing IND Enabling Studies of KIT Inhibitor EPS-1421 • On Track to Announce STAT6 Deve |
|
| January 27, 2025 |
Annual Report 2024We are proud to report that 2024 was marked by progress toward accomplishing many of our goals. |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| January 27, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for |
|
| January 22, 2025 |
EXHIBIT I JOINT FILING AGREEMENT This will confirm the agreement by and among the undersigned that the Schedule 13G filed with the Securities and Exchange Commission on or about the date hereof with respect to the beneficial ownership by the undersigned of the Common Stock, par value $0. |
|
| December 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 9, 2024 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Comm |
|
| December 9, 2024 |
Exhibit 99.1 Enanta Pharmaceuticals Announces Positive Topline Results from First-in-Pediatrics Phase 2 Study Evaluating Zelicapavir for the Treatment of Respiratory Syncytial Virus (RSV) • Observed an antiviral effect for the primary and secondary virology endpoints in the overall population, with a viral load decline of 1.4 log at the end of treatment in Part 2 • Demonstrated a viral load declin |
|
| December 9, 2024 |
Phase 2 Study of Zelicapavir in Children: RSVPEDs Topline Results December 9, 2024 Exhibit 99. |
|
| November 27, 2024 |
Exhibit 10.29 ENANTA PHARMACEUTICALS, INC. 2024 Inducement Stock Incentive Plan Relative Total Stockholder Return Unit Certificate This Relative Total Stockholder Return Unit Certificate confirms that Enanta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, has granted to the person named below (“Participant”) an award (this “Award”) of the number of Relative Total Stockholder Return |
|
| November 27, 2024 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 27, 2024 |
Amended and Restated Securities Trading Policy Exhibit 19.1 Amended and Restated Effective as of November 17, 2023 ENANTA PHARMACEUTICALS, INC. SECURITIES TRADING POLICY 1. BACKGROUND AND PURPOSE The federal securities laws prohibit any member of the Board of Directors (a “Director”) or employee of Enanta Pharmaceuticals, Inc. (the “Company”) (including its subsidiaries) from purchasing or selling Company securities on the basis of material no |
|
| November 27, 2024 |
Amended and Restated Compensation Clawback Policy Exhibit 97.1 Enanta pharmaceuticals, Inc. AMENDED AND RESTATED Compensation Clawback Policy (Effective as of October 2, 2023) 1. Purpose and Administration. Enanta Pharmaceuticals, Inc. (the “Company”) has adopted this amended and restated compensation clawback policy (the “Policy”) to provide for the recovery of certain executive compensation in the event of an accounting restatement resulting fr |
|
| November 27, 2024 |
Form of Performance Share Unit Certificate under 2024 Inducement Stock Incentive Plan Exhibit 10.28 ENANTA PHARMACEUTICALS, INC. 2024 Inducement Stock Incentive Plan Performance Share Unit Certificate This Performance Share Unit Certificate confirms that Enanta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, has granted to the person named below (“Participant”) an award (this “Award”) of the number of Performance Share Units (“PSUs”) set forth above pursuant to the C |
|
| November 27, 2024 |
Exhibit 10.30 SECOND AMENDMENT TO LEASE AGREEMENT THIS SECOND AMENDMENT TO LEASE AGREEMENT (this “Second Amendment”) is made as of July 26, 2024, by and between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (“Landlord”), and ENANTA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS WHEREAS, Landlord and Tenant are now parties to that certain Deed of Lease dated as |
|
| November 27, 2024 |
Form of Notice of Grant of Non-Statutory Stock Option under 2024 Inducement Stock Incentive Plan Exhibit 10.26 Enanta Pharmaceuticals, Inc. NONSTATUTORY STOCK OPTION GRANT NOTICE AND AGREEMENT (2024 INDUCEMENT STOCK INCENTIVE PLAN) This Nonstatutory Stock Option Certificate confirms that Enanta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, has granted to the person named below (“Participant”) a Nonstatutory Stock Option (this “Option”) to purchase the number of shares of the |
|
| November 27, 2024 |
Form of Notice of Grant of Restricted Stock Unit Award under 2024 Inducement Stock Incentive Plan Exhibit 10.27 Enanta Pharmaceuticals, Inc. RESTRICTED STOCK UNIT GRANT NOTICE AND AWARD AGREEMENT (2024 Inducement Stock INCENTIVE PLAN) This notice confirms that Enanta Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, has granted to the person named below (“Participant”) an award (this “Award”) of the number of Restricted Stock Units (the “RSUs”) set forth below pursuant to the Comp |
|
| November 27, 2024 |
Exhibit 10.31 THIRD AMENDMENT TO LEASE AGREEMENT THIS THIRD AMENDMENT TO LEASE AGREEMENT (this “Third Amendment”) is dated as of September 13, 2024, but made effective as of September 1, 2024, by and between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (“Landlord”), and ENANTA PHARMACEUTICALS, INC., a Delaware corporation (“Tenant”). RECITALS A. Landlord and Tenant are now parti |
|
| November 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K x UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as |
|
| November 25, 2024 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year-Ended September 30, 2024 • On Track to Report Topline Results for RSVPEDs, a Phase 2 Study of Zelicapavir in Infants and Children Infected with Respiratory Syncytial Virus (RSV), in December • Announced Positive Topline Results for EDP-323 in a Phase 2a Human Challenge Study of Healthy Adults Infec |
|
| November 25, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 25, 2024 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 14, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G/A 1 armistice-enta093024a2.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 2)* ENANTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29251M106 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) |
|
| October 17, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G/A 1 ENTASC13GA1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (AMENDMENT NO. 1) ENANTA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 29251M106 (CUSIP Number) SEPTEMBER 30, 2024 (Date of event which requires filing of this statement) Check the a |
|
| August 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 5, 2024 |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter • Announces Completion of Enrollment of RSVPEDs, a Phase 2 Study of Zelicapavir in Pediatric Respiratory Syncytial Virus (RSV) Patients; On Track to Report Topline Data in Q4 2024 • Announces Completion of EDP-323 Phase 2a Challenge Study in RSV; On Track to Report Topline Data in Late Q3 2024 • Operations S |
|
| August 5, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 05, 2024 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| May 8, 2024 |
EXHIBIT 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Enanta Pharmaceuticals, Inc. |
|
| May 8, 2024 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 8, 2024 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 8, 2024 REGISTRATION NO. |
|
| May 8, 2024 |
2024 Inducement Stock Incentive Plan Exhibit 99.2 ENANTA PHARMACEUTICALS, INC. 2024 Inducement Stock Incentive Plan 1. Purpose The purpose of this 2024 Inducement Stock Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract persons who are expected to make important contributions to th |
|
| May 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 8, 2024 |
Exhibit 10.2 AMENDED AND RESTATED EMPLOYMENT AGREEMENT This Amended and Restated Employment Agreement (this ''Agreement") dated as of February 8, 2024, by and between Enanta Pharmaceuticals, Inc. (“Employer”), 500 Arsenal Street, Watertown, MA 02472, and Nathaniel S. Gardiner (“Employee”) amends and restates the Employment Agreement (the “Original Agreement”) dated as of April 28, 2014, between Em |
|
| May 6, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 06, 2024 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 6, 2024 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Webcast and Conference Call Today at 4:30 p.m. ET • Anticipates Reporting Topline Data from EDP-323 Respiratory Syncytial Virus (RSV) Challenge Study in Q3 2024 and Phase 2 Study of Zelicapavir in Pediatric RSV Patients in 2H 2024 • Selection of Chronic Spontaneous Urticaria (CSU) Development Candidate |
|
| March 12, 2024 |
2019 Equity Incentive Plan (As amended March 2024) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended through March 6, 2024) 1. Purpose The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected t |
|
| March 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 06, 2024 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| February 26, 2024 |
United States securities and exchange commission logo February 26, 2024 Paul Mellett Chief Financial Officer Enanta Pharmaceuticals, Inc. |
|
| February 14, 2024 |
Enanta Pharmaceuticals, Inc. 500 Arsenal Street, Watertown, Massachusetts 02472 P: (617) 607-0800 February 14, 2024 United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences Washington, D. |
|
| February 14, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / ARMISTICE CAPITAL, LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 5)* Name of issuer: Enanta Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 29251M106 Date of Event Which Requires Filing of this Statement: December 29, 2023 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 7, 2024 |
United States securities and exchange commission logo February 7, 2024 Paul Mellett Chief Financial Officer Enanta Pharmaceuticals, Inc. |
|
| February 7, 2024 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2023 with Webcast and Conference Call Today at 4:30 p.m. ET • Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024 • Expanded into Immunology with New Discovery Program of Oral KIT Inhibitors for First I |
|
| February 7, 2024 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 07, 2024 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 6, 2024 |
[Remainder of this page intentionally left blank] February 5, 2024 VIA EDGAR Securities and Exchange Commission Division of Corporation Finance 100 F Street, N. |
|
| January 26, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / Farallon Capital Partners, L.P. Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| January 26, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| January 26, 2024 |
Annual Report 2023At Enanta, we are always working toward our mission to discover, develop and deliver groundbreaking small molecule drugs for diseases with significant unmet need, and 2023 was an important year that advanced that mission. |
|
| January 24, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment SC 13G/A 1 us29251m1062012424.txt us29251m1062012424.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 4) ENANTA PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 29251M106 - (CUSIP Number) December 31, 2023 - (Date of Event Which Requires Filing of this Statement) Check the appropr |
|
| January 22, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 EXIT FILING ENANTA PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 29251M106 (CUSIP NUMBER) 12/31/2023 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE I |
|
| January 11, 2024 |
ENTA / Enanta Pharmaceuticals, Inc. / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 ENTASC13G2024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ENANTA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 29251M106 (CUSIP Number) JANUARY 5, 2024 (Date of event which requires filing of this statement) Check the appropriate box to des |
|
| December 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 19, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 27, 2023 |
United States securities and exchange commission logo November 27, 2023 Nathaniel S. |
|
| November 22, 2023 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 22, 2023 |
Powers of Attorney (included on the signature pages to the registration statement) Table of Contents As filed with the Securities and Exchange Commission on November 22, 2023 Registration Statement No. |
|
| November 22, 2023 |
As filed with the Securities and Exchange Commission on November 22, 2023 As filed with the Securities and Exchange Commission on November 22, 2023 Registration Statement No. |
|
| November 22, 2023 |
x UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as |
|
| November 22, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-3 (Form Type) Enanta Pharmaceuticals, Inc. |
|
| November 22, 2023 |
Exhibit 4.3 ENANTA PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [ ] Trustee TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions 1 Section 1.02 Other Definitions 4 Section 1.03 Incorporation by Reference of Trust Indenture Act 5 Section 1.04 Rules of Construction 5 ARTICLE II THE SECURITIES 6 Section 2.01 Issuable in Series 6 Section 2.02 Establishm |
|
| November 20, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 20, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 20, 2023 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2023, with Webcast and Conference Call Today at 4:30 p.m. ET • Initiated a Phase 2a Challenge Study of EDP-323,an L-Protein Inhibitor, in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Report Data in Q3 2024 • Streamlined Business a |
|
| November 16, 2023 |
ENTA / Enanta Pharmaceuticals Inc / MILLENNIUM MANAGEMENT LLC Passive Investment SC 13G 1 ENTASC13G.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ENANTA PHARMACEUTICALS, INC. (Name of Issuer) COMMON STOCK, PAR VALUE $0.01 PER SHARE (Title of Class of Securities) 29251M106 (CUSIP Number) NOVEMBER 7, 2023 (Date of event which requires filing of this statement) Check the appropriate box to design |
|
| October 6, 2023 |
ENTA / Enanta Pharmaceuticals Inc / BlackRock Inc. Passive Investment SC 13G/A 1 us29251m1062100523.txt us29251m1062100523.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 3) ENANTA PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 29251M106 - (CUSIP Number) September 30, 2023 - (Date of Event Which Requires Filing of this Statement) Check the approp |
|
| August 8, 2023 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 8, 2023 S-8 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON AUGUST 8, 2023 REGISTRATION NO. |
|
| August 8, 2023 |
EXHIBIT 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Enanta Pharmaceuticals, Inc. |
|
| August 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 07, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 7, 2023 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter with Conference Call and Webcast Today at 4:30 p.m. ET • Reported Positive Topline Data from Phase 1 Study of EDP-323, an L-Protein Inhibitor in Development as an Oral, Once-Daily Treatment for Respiratory Syncytial Virus (RSV); Expect to Initiate Phase 2 Human Challenge Study in Early 4Q 2023. • Cash and Ma |
|
| June 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 07, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| June 7, 2023 |
Company Logo Corporate Presentation June 7, 2023 Exhibit 99.1 Company Logo Corporate Presentation June 7, 2023 Company Logo Forward Looking Statements Disclaimer This presentation contains forward-looking statements concerning our business, operations and financial performance and condition, as well as our plans, objectives and expectations for our research and development programs, our business and the industry in which we operate. Any statemen |
|
| May 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 8, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 08, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 8, 2023 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter with Conference Call and Webcast Today at 4:30 p.m. ET • Reported Positive Topline Data from Phase 2 SPRINT Clinical Study of EDP-235, a 3CL Protease Inhibitor, in Development as an Oral, Once-Daily Treatment for COVID-19 • Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Roy |
|
| April 27, 2023 |
EX-10.1 Exhibit 10.1 Execution Version CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS EXHIBIT BECAUSE IT IS (I) NOT MATERIAL AND (II) OF THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. [***] INDICATES THAT INFORMATION HAS BEEN OMITTED. ROYALTY PURCHASE AGREEMENT BETWEEN ENANTA PHARMACEUTICALS, INC. AND OCM LIFE SCIENCES PORTFOLIO LP DATED AS OF APRIL 25, 2023 TABLE OF CO |
|
| April 27, 2023 |
EX-99.1 Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Announces Sale of a Portion of Global Royalties on MAVYRET® (U.S.)/MAVIRET® (ex-U.S.) (Glecaprevir/Pibrentasvir) to OMERS Life Sciences for $200 Million • Non-Dilutive and Strengthens Balance Sheet • Competitive Process Results in the Sale of 54.5% of the MAVYRET®/MAVIRET® Royalty Interest, Subject to a 1.42x Cap • Sale Proceeds to |
|
| April 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 25, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 10, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 10, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 7, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 02, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 7, 2023 |
2019 Equity Incentive Plan (As amended March 2023) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended through March 2, 2023) 1. Purpose The purpose of this 2019 Equity Incentive Plan (this “Plan”) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who are expected t |
|
| February 14, 2023 |
ENTA / Enanta Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-enta123122.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* ENANTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check t |
|
| February 14, 2023 |
ENTA / Enanta Pharmaceuticals Inc / FIRST MANHATTAN CO Passive Investment SC 13G/A 1 firstmanhattan-enta123122a1.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enanta Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2022 (Date of Event Which Requires Filing of this Statement) Check |
|
| February 9, 2023 |
ENTA / Enanta Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 4)* Name of issuer: Enanta Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 29251M106 Date of Event Which Requires Filing of this Statement: December 30, 2022 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 8, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 8, 2023 |
ENTA / Enanta Pharmaceuticals Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMEMDED FILING ENANTA PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 29251M106 (CUSIP NUMBER) 12/31/2022 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDUL |
|
| February 7, 2023 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2022 with Webcast and Conference Call Today at 4:30 p.m. ET • Completes Enrollment in SPRINT, a Phase 2 Clinical Study of EDP-235, a 3CL Protease Inhibitor Designed as an Oral, Once-Daily Treatment for COVID-19; Topline Data Expected in May • Expects Phase 1 Data of EDP-323, an L-Protein I |
|
| February 7, 2023 |
Annual Report 2022TO OUR SHAREHOLDERS, January 12, 2023 At Enanta, our commitment to developing groundbreaking medicines extends beyond our deep expertise in virology. |
|
| February 7, 2023 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 07, 2023 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 6, 2023 |
SC 13G/A 1 13ga4enanta.htm AMENDMENT #4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 4) * Enanta Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29251M106 (Cusip Number) December 31, 2022 (Date of Event which Requires Filing of this Statement) |
|
| January 31, 2023 |
ENTA / Enanta Pharmaceuticals Inc / BlackRock Inc. Passive Investment SC 13G 1 us29251m1062013123.txt us29251m1062013123.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 2) ENANTA PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 29251M106 - (CUSIP Number) December 31, 2022 - (Date of Event Which Requires Filing of this Statement) Check the appropria |
|
| January 20, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of |
|
| January 20, 2023 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confid |
|
| November 23, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| November 23, 2022 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 21, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 21, 2022 |
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2022 With Webcast and Conference Call Today at 4:30 p. |
|
| August 26, 2022 |
Up to $100,000,000 Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-258632 PROSPECTUS SUPPLEMENT (To Prospectus dated August 9, 2021) Up to $100,000,000 Common Stock We have entered into an Open Market Sale AgreementSM (sales agreement) with Jefferies LLC (Jefferies), dated August 26, 2022, relating to the sale of shares of our common stock offered by this prospectus supplement and the accompa |
|
| August 26, 2022 |
Exhibit 107 Calculation Of Filing Fee Tables 424(b)(5) (Form Type) Enanta Pharmaceuticals, Inc. |
|
| August 26, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 26, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 26, 2022 |
EX-1.1 2 d376393dex11.htm EX-1.1 Exhibit 1.1 OPEN MARKET SALE AGREEMENTSM August 26, 2022 JEFFERIES LLC 520 Madison Avenue New York, New York 10022 Ladies and Gentlemen: Enanta Pharmaceuticals, Inc., a Delaware corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell from time to time through Jefferies LLC, as sales agent and/or principal (the “Ag |
|
| August 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 8, 2022 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET ? Presented Positive Phase 1 Study Data for EDP-235, a Coronavirus 3CL Protease Inhibitor in Development as an Oral, Once-Daily Treatment for COVID-19; Phase 2 Study Planned to Start in 4Q 2022 ? Progressing Respiratory Syncytial Viru |
|
| August 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 08, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| June 22, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 21, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 17, 2022 |
Entry into a Material Definitive Agreement, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 17, 2022 |
Exhibit 10.1 Execution Version SECOND AMENDMENT TO LEASE THIS SECOND AMENDMENT TO LEASE (this ?Second Amendment?) is made as of May 12, 2022, by and between ARE-500 ARSENAL STREET, LLC, a Delaware limited liability company (?Landlord?), and ENANTA PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). RECITALS A. Landlord and Tenant are parties to that certain Lease Agreement dated as of April |
|
| May 17, 2022 |
Exhibit 10.2 Execution Version FIRST AMENDMENT TO LEASE AGREEMENT THIS FIRST AMENDMENT TO LEASE AGREEMENT (this ?Amendment?) is made as of May 12, 2022, by and between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (?Landlord?), and ENANTA PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). RECITALS WHEREAS, Landlord (as successor-in-interest to Athena Arsenal, LLC) and Tena |
|
| May 17, 2022 |
Lease Agreement made as of May 12, 2022 by and between ARE-MA Region No. 75, LLC and the Company Exhibit 10.3 Execution Version LEASE AGREEMENT THIS LEASE AGREEMENT (this ?Lease?) is made as of this 12 day of May, 2022, between ARE-MA REGION NO. 75, LLC, a Delaware limited liability company (?Landlord?), and ENANTA PHARMACEUTICALS, INC., a Delaware corporation (?Tenant?). Building: The to-be-constructed building in the Project to be located at The Arsenal on the Charles campus, Watertown, Mas |
|
| May 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 9, 2022 |
Form of Consulting Agreement (Amended and Restated), Nathalie Adda Exhibit 10.1 CONSULTING AGREEMENT (As Amended and Restated) This Consulting Agreement (this ?Agreement?) is entered into effective as of the 23rd day of February, 2022 (the ?Signature Date?) between Enanta Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, with offices at 500 Arsenal Street, Watertown, MA 02472, and Nathalie Adda, M.D, having a principal residence in Cambridge, Massach |
|
| May 9, 2022 |
Exhibit 99.1 Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2022 With Webcast and Conference Call Today at 4:30 p.m. ET ? Expects Topline Data From RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV), This Quarter ? Received Fast Track Designation for EDP-235, an Oral 3CL Protease Inhibitor Specifical |
|
| May 9, 2022 |
EX-FILING FEES 4 d337268dexfilingfees.htm EX-FILING FEES EXHIBIT 107 Calculation Of Filing Fee Tables Form S-8 (Form Type) Enanta Pharmaceuticals, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Share Maximum Aggregate Offering Price Fee |
|
| May 9, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 09, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissi |
|
| May 9, 2022 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 9, 2022 AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 9, 2022 REGISTRATION NO. |
|
| March 9, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): March 03, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdiction of incorporation) (Commis |
|
| March 8, 2022 |
Financial Statements and Exhibits, Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| March 8, 2022 |
2019 Equity Incentive Plan (as amended through March 3, 2022) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended through March 3, 2022) 1. Purpose The purpose of this 2019 Equity Incentive Plan (this ?Plan?) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected t |
|
| February 15, 2022 |
Exhibit A AGREEMENT The undersigned agree that this Amendment No. 1 to Schedule 13G dated February 14, 2022 relating to the Common Stock, par value $0.01 per share, of Enanta Pharmaceuticals Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd |
|
| February 15, 2022 |
ENTA / Enanta Pharmaceuticals Inc / FIRST MANHATTAN CO Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 15, 2022 |
ENTA / Enanta Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
ENTA / Enanta Pharmaceuticals Inc / ARMISTICE CAPITAL, LLC - SC 13G/A Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 14, 2022 |
Exhibit A AGREEMENT The undersigned agree that this Amendment No. 1 to Schedule 13G dated February 14, 2022 relating to the Common Stock, par value $0.01 per share, of Enanta Pharmaceuticals Inc. shall be filed on behalf of the undersigned. Armistice Capital, LLC By: /s/ Steven Boyd Steven Boyd Managing Member /s/ Steven Boyd Steven Boyd |
|
| February 11, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 11, 2022 |
ENTA / Enanta Pharmaceuticals Inc / STATE STREET CORP Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 AMENDED FILING ENANTA PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 29251M106 (CUSIP NUMBER) 12/31/2021 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDUL |
|
| February 10, 2022 |
ENTA / Enanta Pharmaceuticals Inc / RENAISSANCE TECHNOLOGIES LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* ENANTA PHARMACEUTICALS, INC. - (Name of Issuer) Common Stock, par value $0.01 per share - (Title of Class of Securities) 29251M106 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to d |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 10, 2022 |
ENTA / Enanta Pharmaceuticals Inc / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 3)* Name of issuer: Enanta Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 29251M106 Date of Event Which Requires Filing of this Statement: December 31, 2021 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check one): ☐ Form 10-K ☐ Form 20-F ☐ Form 11-K ☒ Form 10-Q ☐ Form 10-D ☐ Form N-SAR☐ Form N-CSR For Period Ended: December 31, 2021 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q ☐ Transition Report on |
|
| February 8, 2022 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 08, 2022 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 8, 2022 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET ? Expects to Begin Dosing in a First-in-Human Study of EDP-235, an Oral 3CL Protease Inhibitor Specifically Designed for the Treatment of COVID-19, This Month ? Completed Enrollment in RSVP, a Phase 2b Study |
|
| February 4, 2022 |
ENTA / Enanta Pharmaceuticals Inc / Dworsky Alan J - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 8)* ENANTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2021 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| January 28, 2022 |
ENTA / Enanta Pharmaceuticals Inc / BlackRock Inc. Passive Investment us29251m1062012822.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 1) ENANTA PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 29251M106 - (CUSIP Number) December 31, 2021 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a Party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ? Definit |
|
| January 21, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definit |
|
| December 17, 2021 |
ENTA / Enanta Pharmaceuticals Inc / Luly Jay R. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Enanta Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29251M106 (CUSIP Number) Nathaniel S. Gardiner Senior Vice President and General Counsel Enanta Pharmaceuticals, Inc. 500 Arsenal Street |
|
| November 24, 2021 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 24, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| November 24, 2021 |
Consulting Agreement with Nathalie Adda Exhibit 10.28 CONSULTING AGREEMENT This Consulting Agreement (this ?Agreement?) is entered into effective as of the 14th day of July, 2021 (the ?Signature Date?) between Enanta Pharmaceuticals, Inc. (the ?Company?), a Delaware corporation, with offices at 500 Arsenal Street, Watertown, MA 02472, and Nathalie Adda, M.D, having a principal residence in Cambridge, Massachusetts (?Consultant?) (each, |
|
| November 22, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 22, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| November 22, 2021 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET ? Presented First Preclinical Data for EDP-235, an Oral Protease Inhibitor Specifically Designed for the Treatment of COVID-19; First-in-Human Study Planned for Early 2022 ? Reported Positive Clini |
|
| August 23, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 19, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commi |
|
| August 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 9, 2021 |
As filed with the Securities and Exchange Commission on August 9, 2021 As filed with the Securities and Exchange Commission on August 9, 2021 Registration Statement No. |
|
| August 9, 2021 |
Exhibit 4.3 ENANTA PHARMACEUTICALS, INC. INDENTURE Dated as of , 20 [ ] Trustee - 1 - TABLE OF CONTENTS ARTICLE I DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.01 Definitions. 1 Section 1.02 Other Definitions. 4 Section 1.03 Incorporation by Reference of Trust Indenture Act. 5 Section 1.04 Rules of Construction. 5 ARTICLE II THE SECURITIES 6 Section 2.01 Issuable in Series. 6 Section 2.02 |
|
| August 5, 2021 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET ? Nominates EDP-235, an Oral Protease Inhibitor Specifically Designed to Treat COVID-19, with a Phase 1 Study Planned for Early Q1 2022 ? On Track to Dose First Subject in a Phase 1 Study of EDP-721, an Oral, Hep |
|
| August 5, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 5, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| July 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 14, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 10, 2021 |
AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 10, 2021 REGISTRATION NO. |
|
| May 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 6, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| May 6, 2021 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2021 with Webcast and Conference Call Today at 4:30 p.m. ET ? Reported Positive Data from a Phase 1b Study of EDP-514 in NUC-Suppressed Chronic Hepatitis B Virus (HBV) Patients Supporting Once Daily Dosing and Combination Approach ? On Track to Report Preliminary Data f |
|
| March 5, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 2, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| March 5, 2021 |
2019 Equity Incentive Plan (As amended March 2021) Exhibit 10.1 ENANTA PHARMACEUTICALS, INC. 2019 Equity Incentive Plan (As amended March 2021) 1.Purpose The purpose of this 2019 Equity Incentive Plan (this ?Plan?) of Enanta Pharmaceuticals, Inc., a Delaware corporation (the ?Company?), is to advance the interests of the Company?s stockholders by enhancing the Company?s ability to attract, retain and motivate persons who are expected to make impor |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 2) ENANTA PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 29251M106 (CUSIP NUMBER) December 31, 2020 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sc |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 16, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 10, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 2)* Name of issuer: Enanta Pharmaceuticals Inc. Title of Class of Securities: Common Stock CUSIP Number: 29251M106 Date of Event Which Requires Filing of this Statement: December 31, 2020 Check the appropriate box to designate the rule pursuant to which this Schedule is |
|
| February 10, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 ENANTA PHARMACEUTICALS, INC. - (Name of Issuer) Common Stock, par value $0.01 per share - (Title of Class of Securities) 29251M106 - (CUSIP Number) September 18, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 SCHEDULE 13G UNDER THE SECURITIES EXCHANGE ACT OF 1934 ANNUAL FILING ENANTA PHARMACEUTICALS INC (NAME OF ISSUER) COMMON STOCK (TITLE OF CLASS OF SECURITIES) 29251M106 (CUSIP NUMBER) 12/31/2020 (DATE OF EVENT WHICH REQUIRES FILING OF THIS STATEMENT) CHECK THE APPROPRIATE BOX TO DESIGNATE THE RULE PURSUANT TO WHICH THIS SCHEDULE |
|
| February 9, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 8, 2021 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET • Broadened Hepatitis B Virus (HBV) Program with EDP-721, a New Oral HBV RNA Destabilizer, as a Potential Component of a Functional HBV Cure Regimen; Plan to Initiate Phase 1 Study Mid-2021 • Initiated RSVTx, |
|
| February 8, 2021 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Comm |
|
| February 5, 2021 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 5, 2021 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdiction of incorporation) (Comm |
|
| February 5, 2021 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| February 5, 2021 |
CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD LIKELY CAUSE COMPETITIVE HARM TO THE REGISTRANT IF PUBLICLY DISCLOSED. |
|
| January 28, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. 1) Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a- |
|
| January 28, 2021 |
SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 7)* ENANTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2020 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| January 25, 2021 |
us29251m1062012521.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: ) ENANTA PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 29251M106 - (CUSIP Number) December 31, 2020 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule purs |
|
| January 21, 2021 |
- 2022 ENANTA PHARMACEUTICALS PROXY UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Definit |
|
| January 21, 2021 |
DEFA14A 1 enta-defa14a20210121.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only ( |
|
| December 4, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 1, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Comm |
|
| November 25, 2020 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 25, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| November 25, 2020 |
Form of Notice of Restricted Stock Unit Award under 2019 Equity Incentive Plan. Form of Notice of Restricted Stock Unit Award under 2019 Equity Incentive Plan Exhibit 10. |
|
| November 23, 2020 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2020 Webcast and Conference Call Today at 4:30 p.m. ET • On track to initiate a Phase 2b study in adult transplant patients with respiratory syncytial virus by year-end and a Phase 2 study in pediatric patients with respiratory syncytial virus in early 2021 |
|
| November 23, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition - 8-K Q4 2020 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 23, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| August 10, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 4, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 4, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commis |
|
| August 4, 2020 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET • Initiated Phase 1b Study of EDP-514 in Viremic HBV Patients and Resumed Phase 1b Study of EDP-514 in NUC-Suppressed HBV Patients; Preliminary Data Expected in 1H 2021 and 2Q 2021, Respectively • Plans to Initia |
|
| June 30, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 29, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commiss |
|
| May 11, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant |
|
| May 6, 2020 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Second Quarter Ended March 31, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET • On Track to Initiate Phase 1b Study of EDP-514 in Viremic Hepatitis B Patients in 2Q 2020 and Phase 1 Study of EDP-297 in 3Q 2020 • Royalty Revenue for the Quarter was $27.6 Million • Cash and Marketable Secu |
|
| May 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 6, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Commissio |
|
| March 4, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. / Luly Jay R. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enanta Pharmaceuticals, Inc. (Name of Issuer) Common Stock, par value $0.01 per share (Title of Class of Securities) 29251M106 (CUSIP Number) Nathaniel S. Gardiner Senior Vice President and General Counsel Enanta Pharmaceuticals, Inc. 500 Arsena |
|
| March 2, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 26, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| February 14, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. / PRICE T ROWE ASSOCIATES INC /MD/ Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1) ENANTA PHARMACEUTICALS INC (Name of Issuer) COMMON STOCK (Title of Class of Securities) 29251M106 (CUSIP NUMBER) December 31, 2019 (Date of Event which Requires Filing of Statement) Check the appropriate box to designate the Rule pursuant to which this Sc |
|
| February 14, 2020 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. |
|
| February 13, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. / SHIONOGI & CO LTD - SC 13G/A Passive Investment SC 13G/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. 1)* Enanta Pharmaceuticals, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant |
|
| February 12, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. / VANGUARD GROUP INC - SCHEDULE 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Schedule 13G Under the Securities Exchange Act of 1934 (Amendment No.: 1)* Name of issuer: Enanta Pharmaceuticals Inc Title of Class of Securities: Common Stock CUSIP Number: 29251M106 Date of Event Which Requires Filing of this Statement: December 31, 2019 Check the appropriate box to designate the rule pursuant to which this Schedule is f |
|
| February 10, 2020 |
Quarterly Report - ENTA_Q1_FY20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended December 31, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registra |
|
| February 6, 2020 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): February 6, 2020 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdiction of incorporation) (Comm |
|
| February 6, 2020 |
EX-99.1 Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter and Three Months Ended December 31, 2019 Webcast and Conference Call Today at 4:30 p.m. ET • Positive results from part 1 of the Phase 1a/b clinical study of EDP-514 in healthy subjects • Part 2 initiated in nuc-suppressed chronic hepatitis B virus patients • Research and develo |
|
| February 4, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. / BlackRock Inc. Passive Investment us29251m1062020320.txt SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No: 5) ENANTA PHARMACEUTICALS INC - (Name of Issuer) Common Stock - (Title of Class of Securities) 29251M106 - (CUSIP Number) December 31, 2019 - (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 23, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. / Dworsky Alan J - SC 13G/A Passive Investment SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Under the Securities Exchange Act of 1934 (Amendment No. 6)* ENANTA PHARMACEUTICALS, INC. (Name of Issuer) Common Stock (Title of Class of Securities) 29251M106 (CUSIP Number) December 31, 2019 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which this Schedu |
|
| January 17, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. DEFA14A - - DEFA14A DEFA14A 1 d820003ddefa14a.htm DEFA14A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ☒ Filed by a Party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, For Use of the Commission Only (as pe |
|
| January 17, 2020 |
ENTA / Enanta Pharmaceuticals, Inc. DEF 14A - - DEF 14A DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 27, 2019 |
Description of securities registered pursuant to Section 12 of the Securities Exchange Act of 1934 EX-4.3 2 enta-ex43411.htm EX-4.3 Exhibit 4.3 DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934 The following is a description of our common stock and a summary of our preferred stock. You should refer to our Restated Certificate of Incorporation (the “Certificate of Incorporation”) and our Amended and Restated Bylaws (the “Bylaws”), eac |
|
| November 27, 2019 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended September 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as s |
|
| November 27, 2019 |
Exhibit 21.1 Enanta Pharmaceuticals, Inc. Subsidiaries of the Company NAME PARENT STATE OR COUNTRY OF INCORPORATION Enanta Pharmaceuticals Security Corporation Enanta Pharmaceuticals, Inc. Massachusetts |
|
| November 21, 2019 |
Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Fourth Quarter and Year Ended September 30, 2019 Webcast and Conference Call today at 4:30 p.m. ET • Initiation of RSVP, a Phase 2b study of EDP-938 in adult outpatients with RSV • EDP-297 selected as follow-on FXR agonist with differentiated preclinical profile • Royalty revenue for the quarter was |
|
| November 21, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 21, 2019 ENANTA PHARMACEUTICALS, INC. (Exact name of Registrant as Specified in Its Charter) Delaware 001-35839 04-3205099 (State or Other Jurisdiction of Incorporation) (Com |
|
| September 27, 2019 |
ENTA / Enanta Pharmaceuticals, Inc. / FARALLON CAPITAL MANAGEMENT LLC Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. |
|
| August 9, 2019 |
Quarterly Report - Q3 2019 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2019 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 001-35839 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant a |
|
| August 6, 2019 |
EX-99.1 2 enta-ex9916.htm EX-99.1 Exhibit 99.1 For Immediate Release Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2019 Webcast and Conference Call today at 4:30 p.m. ET • Royalty revenue for the quarter was $44.4 million • Phase 2a NASH data expected by the end of the third calendar quarter • Cash and marketable securities totaled $389.2 million at J |
|
| August 6, 2019 |
Financial Statements and Exhibits, Results of Operations and Financial Condition UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report (Date of earliest event reported): August 6, 2019 ENANTA PHARMACEUTICALS, INC. (Exact name of registrant as specified in its charter) Delaware 001-35839 04-3205099 (State or other jurisdiction of incorporation) (Commis |
|
| May 10, 2019 |
ENTA / Enanta Pharmaceuticals, Inc. S-8 S-8 - 2019 AND 2012 EQUITY INCENTIVE PLANS AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 10, 2019 REGISTRATION NO. |
|
| May 10, 2019 |
ENTA / Enanta Pharmaceuticals, Inc. S-8 S-8 2012 EQUITY INCENTIVE PLAN AS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION ON MAY 10, 2019 REGISTRATION NO. |
